[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592218":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":25,"responsibleParty":34,"collaborators":25,"id":38,"slug":25,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":25,"overallStatus":59,"whyStopped":25,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":25},{"fullName":5,"class":6},"National Health Insurance Service Ilsan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lacidofil","EXPERIMENTAL","Take 1 capsule of Lacidofil in the morning and evening after meals, for a total of 2 times a day. The total duration of the dosage is the antibiotic treatment period plus 5 days.",[13],"Drug: Lacidofil",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Take 1 capsule of placebo in the morning and evening after meals, for a total of 2 times a day. The total duration of the dosage is the antibiotic treatment period plus 5 days.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1 capsule twice daily.",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Eunki Chung, MD","CONTACT","+82-31-900-3235","ekchung@nhimc.or.kr",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Eunki Chung","MD","100592218",false,"NCT06990568","Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia","The Effect of Probiotic Administration on the Incidence of Antibiotic-associated Diarrhea in Patients With Community-acquired Pneumonia","PROBIO","Inclusion Criteria:\n\n* Adult patients aged 19 years or older admitted with a diagnosis of community-acquired pneumonia\n* Patients eligible for oral medication administration (able to take oral or enteral feeding)\n\nExclusion Criteria:\n\n* Sepsis patients\n* Patients admitted to the intensive care unit (ICU) following endotracheal intubation\n* Elderly patients aged 80 years or older\n* Pregnant women\n* Patients who have diarrhea at the time of admission\n* Patients with a history of using probiotics within 3 months prior to admission\n* Patients with a history of using laxatives within 1 week prior to admission\n* Patients suspected of being in shock (mean arterial pressure \\\u003C 65 mmHg) at the time of admission","ALL","19 Years","79 Years",{"count":49,"type":50},100,"ESTIMATED","INTERVENTIONAL",[53],"PHASE4","The study goal is to determine whether oral administration of a probiotic mixture can reduce the incidence of antibiotic-associated diarrhea in patients with community-acquired pneumonia.",[56,57,58],"Pneumonia","Probiotics","Diarrhea","NOT_YET_RECRUITING","2025-05-23",{"date":62,"type":63},"2025-05-25","ACTUAL",{"date":65,"type":50},"2025-06-01",{"date":67,"type":50},"2026-12-31",{"name":5,"class":6}]